Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

Inclusion Criteria:

• Has completed double-blind treatment in either of the lead-in efficacy trials, 000079or 000080.

• The patient reports having understood and has signed the Informed Consent Form (ICF)and is willing to comply with all trial visits and assessments.

• The patient agrees to refrain from making any new, major lifestyle changes that mayaffect CIC symptoms (i.e., starting a new diet, changing an exercise plan) from thetime of signing the ICF through to the last trial visit.

Exclusion Criteria:

• The patient has been withdrawn/discontinued from the 000079 or 000080 trials.

• The patient is not willing to abide by the restrictions for intake of prohibitedmedication.

• Women of childbearing potential (defined, for the purpose of this trial, as allfemales post-puberty, not postmenopausal ≥2 years, or not surgically sterile) who havea positive urine pregnancy test at Visit 1, or who do not agree to use one of thefollowing methods of birth control from the day of signing the ICF until 30 days afterthe final dose of trial drug are excluded:

1. Transdermal patch

2. Established use of oral, injected or implanted hormonal methods of contraception

3. Placement of an intrauterine device (IUD) or intrauterine system (IUS).

4. Barrier methods of contraception: Condom or Occlusive cap (diaphragm orcervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

5. Male sterilisation (with the appropriate post-vasectomy documentation of theabsence of sperm in the ejaculate).

6. True sexual abstinence: when this is in line with the preferred and usuallifestyle of the patient.

• The patients is considered by the Investigator to be unsuitable to participate in thetrial for any other reason.